市場調査レポート

商品コード

インスリン市場の2028年までの予測-タイプ別・地域別の世界分析

Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Geography

出版日: 2022年07月29日 | 発行: The Insight Partners

| ページ情報: 英文 255 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 4,550 714,987円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 6,550 1,029,267円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 8,550 1,343,547円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

インスリン市場は、2021年の546億1142万米ドルから、2028年には1112億1373万米ドルに成長すると予測されています。2022年から2028年までのCAGRは10.8%で成長すると予測されています。

糖尿病の発症率の上昇と、主要プレイヤーによるインスリン送達デバイスの急速な技術開拓が、今後数年間でインスリン市場を強化すると予想されます。さらに、高度な移植による糖尿病性膵臓の再生は、2022年から2028年にかけて、インスリン市場の重要な将来動向として浮上すると思われます。しかし、インスリン送達デバイスに関連するリスクは、市場全体の成長を阻害します。

糖尿病患者の場合、膵臓から十分なインスリンが分泌されない、あるいは体が通常インスリンに反応しないため、血糖値が上昇します。インスリンは、血糖値を下げるのに役立つホルモンです。インスリン療法は、多くの場合、糖尿病治療において不可欠なものです。膵臓のβ細胞で作られ、食後などグルコースレベルが上昇したときに血液中に放出されます。インスリンは、ブドウ糖が体細胞に入り、エネルギーとして使われたり、将来のために貯蔵されたりするのを助けます。インスリンの種類によって、血糖値をコントロールするスピードと時間が異なります。インスリンは、消化器官で分解されてしまうので、錠剤にはなっていません。インスリン療法は疲れるが、血糖値を下げる効果的な方法です。

糖尿病の治療には、より多くの効果をもたらす高度なインスリン技術を搭載した製品が大きな要件となります。ここ数年、糖尿病治療の進歩は目覚しいものがあります。糖尿病の有病率が世界的に上昇していることから、先進的な製品への需要も高まっています。インスリン市場は、業界各社による戦略的な取り組みの増加により、拡大が見込まれています。市場関係者は、研究活動を活発化させるために、公的・私的な研究機関や学術機関を積極的に支援しています。

インスリン市場の急速な技術進歩に関連する最近の動向のいくつかを以下に紹介します。

2022年5月、イーライリリー・アンド・カンパニーは、2型糖尿病の成人の治療のための週1回投与のグルコース依存性インスリントロピックポリペプチド（GIP）およびグルカゴン様ペプチド-1（GLP-1）受容体アゴニストMounjar（tirzepatide）に対する米国のFDA承認を取得しました。注射剤は、6用量（2.5mg、5mg、7.5mg、10mg、12.5mg、15mg）をあらかじめ隠し針が付いた自動注射器ペンで発売することを決定しています。

2022年4月、アボットは、CamDiabおよびYpsomedと提携し、24時間体制の糖尿病管理のための統合型自動インスリン送達（AID）システムを開発し、商業化することを決定しました。

2021年10月、東方東方製薬株式会社は、超速効型インスリンリスプロ注射剤「BCリスプロ」の臨床試験の承認を国家医療製品管理局（NMPA）より取得しました。現在、中国において第Ⅲ相臨床試験を実施中です。

2021年5月には、ビッグフットバイオメディカル社が、1日複数回注射（MDI）療法を行う人にインスリン投与量を推奨するスマートペンキャップを接続した「ビッグフットユニティ糖尿病管理システム」について米国FDAから510（k）認証を取得しました。

このように、インスリン送達デバイスの急速な技術的進歩が、世界のインスリン市場の成長を後押ししています。

インスリン市場は、タイプと地域に二分されます。タイプ別に見ると、世界のインスリン市場は、長時間作用型インスリン、短時間作用型インスリン＆従来のヒトインスリン、バイオシミラーインスリン、ペン＆針、速効型インスリン、濃縮インスリン＆配合インスリン、グルカゴン様ペプチド-1（GLP-1）、ペン＆針、その他に区分されています。長時間作用型インスリンセグメントは、2022-2028年の間に最大のシェアを占めると推定されます。長時間作用型インスリンアナログは、遺伝子工学的に設計されています。長時間作用型インスリンアナログは、当初、夜間を通して健康的な血糖値を維持するという糖尿病患者のニーズに対応するために開発されました。このインスリンは、その酸性pHにより、皮下注射されると沈殿を起こし、ゆっくりと循環中に放出されます。長時間作用型インスリンは、基礎インスリンまたはバックグラウンドインスリンとも呼ばれます。これらの長時間作用型インスリンは、一日中血糖をコントロールするのに役立ちます。これは、膵臓が食事と食事の間の血糖値を維持するためにインスリンを生成するのと同様です。

インスリン市場の機会

米国などの新興国における主要プレイヤーの優位性が、世界のインスリン市場価値の上昇につながっています。Novo Nordisk A/S、Elli Lily and Company、Sanofiは、90%以上の累積市場収益を上げています。これは主に、これらの支配的なプレーヤーによって現在保持されている特許の常緑化に起因するものです。さらに、米国におけるインスリンの価格上昇は、インスリン市場をさらに押し上げると推定されます。米国疾病管理予防センターによると、米国の医療費4米ドルのうち1米ドルが糖尿病患者のために費やされています。

さらに、バイオシミラー医薬品に対する患者の信頼の低さが、インスリン市場を大きく後押ししています。また、市場の中心的な地域である北米ではバイオシミラー医薬品の競合が不足していることも、市場の成長に拍車をかけると予想されます。Health Action Internationalが実施した調査（2019年）によると、米国ではイーライリリー・アンド・カンパニー、ノボノルディスク、サノフィの3社のみがインスリンを製造しており、世界市場における収益の約90%を生み出しています。一方、アジア太平洋地域には、上記の調査によると、8社以上のインスリンメーカーが存在します。

世界保健機関（WHO）、疾病管理予防センター（CDC）、労働安全衛生局（OSHA）、食品医薬品局（FDA）、個別化医療センター（CPM）、経済協力開発機構（OECD）などは、インスリン市場のレポートを作成する際に参照した一次情報および二次情報の一つです。

市場促進要因
- 糖尿病罹患率の増加
- 主要プレイヤーによるインスリンデリバリーデバイスの急速な技術開発
市場抑制要因
- インスリンデリバリーデバイスに関連するリスク
市場機会
- バイオシミラーとの不十分な競合
今後の動向
- 先進的な移植別糖尿病性膵臓の再生
インパクト分析

第6章インスリン市場-世界分析

インスリンの世界市場収益と予測・分析
- インスリンの世界市場、地域別予測・分析
- インスリンの世界市場-市場ポテンシャル分析、地域別
企業分析
- 主要プレイヤーの市場ポジショニング
- 企業比較分析
- 成長戦略分析
- 主要プレイヤーの業績
  - ノボノルディスクA/S
  - サノフィ
  - イーライリリー・アンド・カンパニー
カスタマイズ部分
- 企業別マーケットシェア分析
- 注射剤GLP別市場シェア分析

第7章インスリン市場分析-タイプ別

インスリン市場タイプ別売上高シェア（2021年、2028年）
長時間作用型インスリン
速効型インスリン
短時間作用型インスリンと従来のヒト型インスリン
濃縮インスリンと配合インスリン
バイオシミラーインスリン
グルカゴン様ペプチド-1（GLP-1）
ペン・ニードル
その他

第8章インスリンの世界市場- 地域別分析

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他欧州
アジア太平洋地域
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他アジア太平洋地域
中東・アフリカ地域
- UAE
- サウジアラビア
- 南アフリカ共和国
- その他中東地域
中南米地域
- ブラジル
- アルゼンチン
- その他の中南米地域

第9章 COVID-19のパンデミックが世界のインスリン市場に与える影響

北米
欧州
アジア太平洋地域
中東およびアフリカ
中南米

第10章インスリン市場-業界情勢

インスリン市場の成長戦略（%）
オーガニック開発
インオーガニック開発

第11章企業プロファイル

Eli Lilly and Company
Novo Nordisk A/S
Biocon
WOCKHARDT
Adocia
GlaxoSmithKline plc.
Sanofi
Pfizer Inc.
Merck & Co., Inc.
Tonghua Dongbao Pharmaceutical Co., Ltd.
BIGFOOT BIOMEDICAL, INC.

第12章付録

The Insight Partners について
用語解説

図表

List Of Tables

Table 1. North America: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. North America: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 3. North America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 6. North America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 7. US: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. US: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 9. US: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 10. US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million) 97
Table 11. US: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 12. US: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada: Insulin Market , By Type - Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 15. Canada: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 16. Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 17. Canada: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 18. Canada: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 21. Mexico: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 22. Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 23. Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 24. Mexico: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 25. Europe: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 26. Europe: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 27. Europe: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 28. Europe: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 29. Europe: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 30. Europe: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 31. Germany: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 32. Germany: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 33. Germany: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 34. Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 35. Germany: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 36. Germany: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 37. France: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 38. France : Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 39. France : Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 40. France : Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 41. France : Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 42. France : Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 43. UK: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 44. UK: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 45. UK: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 46. UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 47. UK: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 48. UK: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 49. Italy: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 50. Italy: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 51. Italy: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 52. Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 53. Italy: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 54. Italy: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 55. Spain: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 56. Spain: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 57. Spain: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 58. Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 59. Spain: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 60. Spain: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 63. Rest of Europe: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 65. Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 66. Rest of Europe: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 67. Asia Pacific: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 68. Asia Pacific: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 69. Asia Pacific: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 70. Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 71. Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 72. Asia Pacific: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 73. China: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 74. China: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 75. China: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 76. China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 77. China: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 78. China: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 79. Japan: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 80. Japan: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 81. Japan: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 82. Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 83. Japan: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 84. Japan: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 85. India: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 86. India: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 87. India: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 88. India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 89. India: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 90. India: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 91. Australia: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 92. Australia: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 93. Australia: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 94. Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 95. Australia: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 96. Australia: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 97. South Korea: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 98. South Korea: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 99. South Korea: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 100. South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 101. South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 102. South Korea: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 103. Rest of Asia Pacific: Insulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 104. Rest of Asia Pacific: Insulin Market, by Long Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 105. Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 109. Middle East & Africa : Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 110. Middle East & Africa : Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 111. Middle East & Africa : Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 112. Middle East & Africa : Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 113. Middle East & Africa : Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 114. Middle East & Africa : Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 115. UAE: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 116. UAE: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 117. UAE: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 118. UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 119. UAE: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 120. UAE: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 121. Saudi Arabia: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 122. Saudi Arabia: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 123. Saudi Arabia: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 124. Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 125. Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 126. Saudi Arabia: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 127. South Africa: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 128. South Africa: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 129. South Africa: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 130. South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 131. South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 132. South Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 133. Rest of Middle East & Africa: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 134. Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 135. Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 136. Rest of Middle East & Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 137. Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 138. Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 139. South and Central America: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 140. South and Central America: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 141. South and Central America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 142. South and Central America: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 143. South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 144. South and Central America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 145. Brazil: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 146. Brazil: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 147. Brazil: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 148. Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 149. Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 150. Brazil: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 151. Argentina: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 152. Argentina: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 153. Argentina: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 154. Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 155. Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 156. Argentina: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 157. Rest of South and Central America: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 158. Rest of South and Central America: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 159. Rest of South and Central America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 160. Rest of South and Central America: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 161. Rest of South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 162. Rest of South and Central America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 163. Organic Developments in the Insulin Market
Table 164. Inorganic Developments in the Insulin Market
Table 165. Glossary of Terms, Insulin Market

List Of Figures

Figure 1. Insulin Market Segmentation
Figure 2. Insulin Market Segmentation, By Region
Figure 3. Global Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Global Insulin Market, By Geography (US$ Million)
Figure 7. Global Insulin Market- Leading Country Markets (US$ Million)
Figure 8. Global Insulin Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East & Africa PEST Analysis
Figure 13. South & Central America PEST Analysis
Figure 14. Expert Opinion
TABLE 1. PREVALENCE OF DIABETES WORLDWIDE, 2021
Figure 15. Insulin Market Impact Analysis of Drivers and Restraints
Figure 16. Global Insulin Market- Revenue Forecast and Analysis - 2020 - 2028
Figure 17. Global Insulin Market - By Geography Forecast and Analysis - 2021 - 2028
Figure 18. Global Insulin Market - Market Potential Analysis, By Region
Figure 19. Market Positioning of Key Players In Global Insulin Market
Figure 20. Global Insulin Market - Comparative Company Analysis
Figure 21. Global Insulin Market - Growth Strategy Analysis
Figure 22. Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 23. Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 38. Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 41. Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 44. Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 46. Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. North America Insulin Market, by Key Country - Revenue (2021) (US$ Million)
Figure 50. North America Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 51. North America: Insulin Market, by Country, 2021 & 2028 (%)
Figure 52. US: Insulin market - Revenue and Forecast to 2028 (US$ Million)
Figure 53. Canada: Insulin market - Revenue and Forecast to 2028 (US$ Million)
Figure 54. Mexico: Insulin market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. Europe: Insulin Market, by Key Country - Revenue (2021) (US$ Million)
Figure 56. Europe Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 57. Europe: Insulin Market, by Country, 2021 & 2028 (%)
Figure 58. Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 59. France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Asia Pacific: Insulin Market, by Key Country - Revenue (2021) (US$ Million)
Figure 65. Asia Pacific: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 66. Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
Figure 67. China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 68. Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 69. India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 71. South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 72. Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 73. Middle East & Africa Insulin Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 74. Middle East & Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 75. Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
Figure 76. UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 77. Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 78. South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 79. Rest of Middle East & Africa: Insulin MarketRevenue and Forecast to 2028 (US$ Million)
Figure 80. South and Central America Insulin Market Revenue Overview, By Country (2021) (US$ Mn)
Figure 81. South and Central America Insulin Market Revenue and Forecast to 2028 (USD Million)
Figure 82. South and Central America Insulin Market Revenue and Forecast to 2028, by Country (%)
Figure 83. Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
Figure 84. Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
Figure 85. Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
Figure 86. Impact Of COVID-19 Pandemic in North American Country Markets
Figure 87. Impact Of COVID-19 Pandemic in Europe Country Markets
Figure 88. Impact of COVID-19 Pandemic in Asia Pacific Countries
Figure 89. Impact Of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 90. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 91. Growth Strategies in the Insulin Market (%)

Product Code: TIPRE00004051

The insulin market is projected to grow from US$ 54,611.42 million in 2021 to US$ 111,213.73 million by 2028. It is expected to grow at a CAGR of 10.8 % from 2022 to 2028.

The increase in the incidence of diabetes and rapid technological developments in insulin delivery devices by major players is expected to bolster the insulin market in the years to come. Additionally, the regeneration of the diabetic pancreas with advanced transplants is likely to emerge as a significant future trend in the insulin market from 2022 to 2028. However, the risks associated with insulin delivery devices hamper the overall market growth.

In diabetic people, the pancreas does not produce enough insulin, or the body does not usually respond to the insulin, increasing the blood glucose level. Insulin is a hormone that helps in lowering blood sugar levels. Insulin therapy is often an essential part of diabetes treatment. It is made by the beta cells of the pancreas and released into the blood when glucose levels rise, for example, after eating. Insulin helps glucose get into the body cells, which can be used for energy or stored for future use. Different types of insulin available vary in how quickly and for how long they can control blood sugar. Insulin does not come in pill form as the digestive system would break it down before it could work. Insulin therapy is exhausting; however, it is an effective way of lowering blood sugar levels.

Products with advanced insulin technology with more benefits are a major requirement in treating diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing worldwide, the demand for advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities.

A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below:

In May 2022, Eli Lilly and Company received US FDA approval for its Mounjar (tirzepatide) once-weekly Glucose-Dependent Insulinotropic Polypeptide (GIP) and GLP-1 Glucagon-like Peptide-1 (GLP-1) receptor agonist for the treatment of adults with type 2 diabetes. The injection is decided to be available in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) as an auto-injector pen with a preattached hidden needle.

In April 2022, Abbott partnered with CamDiab and Ypsomed to develop and commercialize an integrated automated insulin delivery (AID) system for around-the-clock diabetes management.

In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin lispro injection, BC Lispro. Currently, the drug is under phase III clinical trial in China.

In May 2021, Bigfoot Biomedical received 510(k) clearance by the US FDA for its Bigfoot Unity Diabetes Management System, which features connected smartpen caps that recommend insulin doses for people using multiple daily injections (MDI) therapy.

Thus, rapid technological advancements in insulin delivery devices are boosting the growth of the global insulin market.

The insulin market is bifurcated into type and geography. Based on type, the global insulin market is segmented into long-acting insulin, short-acting insulin & traditional human insulin, biosimilar insulin, pen & needle, rapid-acting insulin, concentrated insulin & combination insulin, glucagon-like-peptide-1 (GLP-1), pen & needle, and others. The long-acting insulin segment is estimated to account for the largest share during 2022-2028. Longer-acting insulin analogs are genetically engineered. Long-acting insulin analogs were initially developed to address the need of diabetics to maintain healthy blood sugar levels throughout the night. This insulin is slowly released into the circulation due to its acidic pH, causing it to precipitate when injected subcutaneously. Long-acting insulins are also called basal or background insulins. These long-acting insulins help in controlling blood sugar for a whole day. This is similar to how the pancreas produces insulin to maintain blood sugar levels between meals.

Opportunities in Insulin Market

The dominance of major players in developed countries, such as the US, has led to an increase in the global insulin market value. Novo Nordisk A/S, Elli Lily and Company, and Sanofi have a cumulative market revenue of over 90%. This is majorly credited to the evergreening of patents currently held by these dominating players. Additionally, the rising price of insulin in the US is estimated to boost the insulin market further. According to the Centers for Disease Control and Prevention, US$ 1 out of every US$ 4 in US health care costs is expended on diabetic patients.

Moreover, patients' lack of trust in biosimilar drugs is significantly propelling the insulin market. The shortage of biosimilar competition in the market-dominating region of North America is also expected to fuel the market growth. According to a study conducted by Health Action International (2019), Eli Lilly and Company, Novo Nordisk, and Sanofi are the only three manufacturers of insulin in the US, and they generate around 90% of revenue in the global market. In contrast, there are more than eight insulin manufacturers in Asia Pacific, according to the above study.

The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Occupational Safety and Health Administration (OSHA), Food and Drug Administration (FDA), Centers for Personalized Medicine (CPM), and Organizations for Economic Co-operation and Development (OECD) are among the primary and secondary sources referred to while preparing the report on the insulin market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the insulin market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global insulin market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Insulin Market - By Type
- 1.3.2 Global Insulin Market - By Geography

2. Insulin Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Insulin Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America- PEST Analysis
- 4.2.2 Europe- PEST Analysis
- 4.2.3 Asia Pacific- PEST Analysis
- 4.2.4 Middle East & Africa- PEST Analysis
- 4.2.5 South & Central America- PEST Analysis
- 4.2.6 Expert Opinion

5. Insulin Market- Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Incidence of Diabetes
- 5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
- 5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
- 5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
- 5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis

6. Insulin Market- Global Analysis

6.1 Global Insulin Market Revenue Forecast and Analysis
- 6.1.1 Global Insulin Market, By Geography - Forecast and Analysis
- 6.1.2 Global Insulin Market - Market Potential Analysis, By Region
6.2 Company Analysis
- 6.2.1 Market Positioning of Key Players
- 6.2.2 Comparative Company Analysis
- 6.2.3 Growth Strategy Analysis
- 6.2.4 Performance Of Key Players
  - 6.2.4.1 Novo Nordisk A/S
  - 6.2.4.2 Sanofi
  - 6.2.4.3 Eli Lily and Company
6.3 Customization Part
- 6.3.1 Market Share Analysis by Company
- 6.3.2 Market Share by Injectable GLPs

7. Insulin Market Analysis - By Type

7.1 Overview
7.2 Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
- 7.3.1 Overview
- 7.3.2 Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.1 Levemir
    - 7.3.2.1.1 Overview
    - 7.3.2.1.2 Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.2 Lantus
    - 7.3.2.2.1 Overview
    - 7.3.2.2.2 Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.3 Basaglar
    - 7.3.2.3.1 Overview
    - 7.3.2.3.2 Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.4 Tresiba
    - 7.3.2.4.1 Overview
    - 7.3.2.4.2 Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
- 7.4.1 Overview
- 7.4.2 Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.1 Novolog
    - 7.4.2.1.1 Overview
    - 7.4.2.1.2 Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.2 Humalog
    - 7.4.2.2.1 Overview
    - 7.4.2.2.2 Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.3 Admelog
    - 7.4.2.3.1 Overview
    - 7.4.2.3.2 Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.4 Others
    - 7.4.2.4.1 Overview
    - 7.4.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
- 7.5.1 Overview
- 7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.1 Novolin R
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.2 Humulin R
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.3 Insuman
    - 7.5.2.3.1 Overview
    - 7.5.2.3.2 Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.4 Others
    - 7.5.2.4.1 Overview
    - 7.5.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
- 7.6.1 Overview
- 7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.1 NovoMix
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.2 Ryzodeg
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.3 Xultophy
    - 7.6.2.3.1 Overview
    - 7.6.2.3.2 Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.4 Soliqua/Suliqua
    - 7.6.2.4.1 Overview
    - 7.6.2.4.2 Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
- 7.7.1 Overview
- 7.7.2 Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.1 Insulin Glargine
    - 7.7.2.1.1 Overview
    - 7.7.2.1.2 Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.2 Human Insulin
    - 7.7.2.2.1 Overview
    - 7.7.2.2.2 Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
- 7.8.1 Overview
- 7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
- 7.9.1 Overview
- 7.9.2 Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Insulin Market - Geographic Analysis

8.1 North America: Insulin Market
- 8.1.1 Overview
- 8.1.2 North America: Insulin market - Revenue and Forecast to 2028 (US$ Million)
- 8.1.3 North America: Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.1.3.1 North America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.1.3.2 North America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.1.3.3 North America: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.1.3.4 North America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.1.3.5 North America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.1.4 North America: Insulin Market, by Country, 2021 & 2028 (%)
  - 8.1.4.1 US: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.1.1 US: Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.1.2 US: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.4.1.2.1 US: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.1.2.2 US: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.1.2.3 US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.4.1.2.4 US: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.4.1.2.5 US: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.1.4.2 Canada: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.2.1 Canada: Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.2.2 Canada: Insulin Market , By Type, 2019-2028 (US$ Million)
    - 8.1.4.2.2.1 Canada: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.2.2.2 Canada: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.2.2.3 Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.4.2.2.4 Canada: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.4.2.2.5 Canada: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.1.4.3 Mexico: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.3.1 Mexico: Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.3.2 Mexico: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.4.3.2.1 Mexico: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.3.2.2 Mexico: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.3.2.3 Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.4.3.2.4 Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.4.3.2.5 Mexico: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.2 Europe: Insulin Market
- 8.2.1 Overview
- 8.2.2 Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Europe: Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.2.3.1 Europe: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.2.3.2 Europe: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.2.3.3 Europe: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.2.3.4 Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.2.3.5 Europe: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.2.4 Europe: Insulin Market, by Country, 2021 & 2028 (%)
  - 8.2.4.1 Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.1.1 Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.1.2 Germany: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.1.2.1 Germany: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.1.2.2 Germany: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.1.2.3 Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.1.2.4 Germany: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.1.2.5 Germany: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.2 France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.2.1 France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.2.2 France : Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.2.2.1 France : Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.2.2.2 France : Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.2.2.3 France : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.2.2.4 France : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.2.2.5 France : Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.3 UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.3.1 UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.3.2 UK: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.3.2.1 UK: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.3.2.2 UK: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.3.2.3 UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.3.2.4 UK: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.3.2.5 UK: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.4 Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.4.1 Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.4.2 Italy: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.4.2.1 Italy: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.4.2.2 Italy: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.4.2.3 Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.4.2.4 Italy: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.4.2.5 Italy: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.5 Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.5.1 Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.5.2 Spain: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.5.2.1 Spain: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.5.2.2 Spain: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.5.2.3 Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.5.2.4 Spain: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.5.2.5 Spain: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.6 Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.6.1 Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.6.2 Rest of Europe: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.6.2.1 Rest of Europe: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.6.2.2 Rest of Europe: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.6.2.3 Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.6.2.4 Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.6.2.5 Rest of Europe: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.3 Asia Pacific: Insulin Market
- 8.3.1 Overview
- 8.3.2 Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
- 8.3.3 Asia Pacific: Insulin Market, by Type, 2019-2028 (US$ Million)
  - 8.3.3.1 Asia Pacific: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.3.3.2 Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
  - 8.3.3.3 Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.3.3.4 Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.3.3.5 Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.3.4 Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
  - 8.3.4.1 China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.1.1 China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.1.2 China: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.1.2.1 China: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.1.2.2 China: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.1.2.3 China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.1.2.4 China: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.1.2.5 China: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.2 Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.2.1 Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.2.2 Japan: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.2.2.1 Japan: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.2.2.2 Japan: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.2.2.3 Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.2.2.4 Japan: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.2.2.5 Japan: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.3 India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.3.1 India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.3.2 India: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.3.2.1 India: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.3.2.2 India: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.3.2.3 India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.3.2.4 India: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.3.2.5 India: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.4 Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.4.1 Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.4.2 Australia: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.4.2.1 Australia: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.4.2.2 Australia: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.4.2.3 Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.4.2.4 Australia: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.4.2.5 Australia: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.5 South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.5.1 South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.5.2 South Korea: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.5.2.1 South Korea: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.5.2.2 South Korea: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.5.2.3 South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.5.2.4 South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.5.2.5 South Korea: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.6 Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.6.1 Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.6.2 Rest of Asia Pacific: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.6.2.1 Rest of Asia Pacific: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.6.2.2 Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.6.2.3 Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.6.2.4 Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.6.2.5 Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
8.4 Middle East & Africa Insulin Market Revenue and Forecasts To 2028
- 8.4.1 Overview
- 8.4.2 Middle East & Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
- 8.4.3 Middle East & Africa : Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.4.3.1 Middle East & Africa : Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.4.3.2 Middle East & Africa : Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.4.3.3 Middle East & Africa : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.4.3.4 Middle East & Africa : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.4.3.5 Middle East & Africa : Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.4.4 Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
  - 8.4.4.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.1.2 UAE: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.1.2.1 UAE: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.1.2.2 UAE: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.1.2.3 UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.1.2.4 UAE: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.1.2.5 UAE: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.4.4.2 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.2.1 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.2.2 Saudi Arabia: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.2.2.1 Saudi Arabia: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.2.2.2 Saudi Arabia: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.2.2.3 Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.2.2.4 Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.2.2.5 Saudi Arabia: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.4.4.3 South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.3.1 South Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.3.2 South Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.3.2.1 South Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.3.2.2 South Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.3.2.3 South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.3.2.4 South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.3.2.5 South Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.4.4.4 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.4.1 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.4.2 Rest of Middle East & Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.4.2.1 Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.4.2.2 Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.4.2.3 Rest of Middle East & Africa: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.4.2.4 Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.4.2.5 Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.5 South and Central America Insulin Market Revenue and Forecasts To 2028
- 8.5.1 Overview
- 8.5.2 South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
- 8.5.3 South and Central America: Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.5.3.1 South and Central America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.5.3.2 South and Central America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.5.3.3 South and Central America: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.5.3.4 South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.5.3.5 South and Central America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.5.4 South and Central America Insulin Market Revenue and Forecast to 2028, by Country (%)
  - 8.5.4.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.1.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.1.2 Brazil: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.5.4.1.2.1 Brazil: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.1.2.2 Brazil: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.1.2.3 Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.5.4.1.2.4 Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.5.4.1.2.5 Brazil: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.5.4.2 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.2.1 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.2.2 Argentina: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.5.4.2.2.1 Argentina: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.2.2.2 Argentina: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.2.2.3 Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.5.4.2.2.4 Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.5.4.2.2.5 Argentina: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.5.4.3 Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.3.1 Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.3.2 Rest of South and Central America: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.5.4.3.2.1 Rest of South and Central America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.3.2.2 Rest of South and Central America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.3.2.3 Rest of South and Central America: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.5.4.3.2.4 Rest of South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.5.4.3.2.5 Rest of South and Central America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)

9. Impact of COVID-19 Pandemic on Global Insulin Market

9.1 North America: Impact Assessment of COVID-19 Pandemic
9.2 Europe: Impact Assessment of COVID-19 Pandemic
9.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
9.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
9.5 South and Central America: Impact Assessment of COVID-19 Pandemic

10. Insulin Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Insulin Market (%)
10.3 Organic Developments
- 10.3.1 Overview
10.4 Inorganic Developments
- 10.4.1 Overview

11. Company Profile

11.1 Eli Lilly and Company
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Novo Nordisk A/S
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Biocon
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 WOCKHARDT
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Adocia
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 GlaxoSmithKline plc.
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Sanofi
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Pfizer Inc.
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Merck & Co., Inc.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Tonghua Dongbao Pharmaceutical Co., Ltd.
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments
11.11 BIGFOOT BIOMEDICAL, INC.
- 11.11.1 Key Facts
- 11.11.2 Business Description
- 11.11.3 Products and Services
- 11.11.4 Financial Overview
- 11.11.5 SWOT Analysis
- 11.11.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

インスリン市場の2028年までの予測-タイプ別・地域別の世界分析

Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Geography

目次

第1章イントロダクション

第2章インスリンの世界市場-主要なポイント

第3章調査手法

第4章インスリン市場- 市場情勢

第5章インスリン市場-主要な市場力学

第6章インスリン市場-世界分析

第7章インスリン市場分析-タイプ別

第8章インスリンの世界市場- 地域別分析

第9章 COVID-19のパンデミックが世界のインスリン市場に与える影響

第10章インスリン市場-業界情勢

第11章企業プロファイル

第12章付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Insulin Market - Key Takeaways

3. Research Methodology

4. Insulin Market - Market Landscape

5. Insulin Market- Key Market Dynamics

6. Insulin Market- Global Analysis

7. Insulin Market Analysis - By Type

8. Global Insulin Market - Geographic Analysis

9. Impact of COVID-19 Pandemic on Global Insulin Market

10. Insulin Market-Industry Landscape

11. Company Profile

12. Appendix

インスリン市場の2028年までの予測-タイプ別・地域別の世界分析

Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Geography

目次

第1章 イントロダクション

第2章 インスリンの世界市場-主要なポイント

第3章 調査手法

第4章 インスリン市場- 市場情勢

第5章 インスリン市場-主要な市場力学

第6章 インスリン市場-世界分析

第7章 インスリン市場分析-タイプ別

第8章 インスリンの世界市場- 地域別分析

第9章 COVID-19のパンデミックが世界のインスリン市場に与える影響

第10章 インスリン市場-業界情勢

第11章 企業プロファイル

第12章 付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Insulin Market - Key Takeaways

3. Research Methodology

4. Insulin Market - Market Landscape

5. Insulin Market- Key Market Dynamics

6. Insulin Market- Global Analysis

7. Insulin Market Analysis - By Type

8. Global Insulin Market - Geographic Analysis

9. Impact of COVID-19 Pandemic on Global Insulin Market

10. Insulin Market-Industry Landscape

11. Company Profile

12. Appendix

第1章イントロダクション

第2章インスリンの世界市場-主要なポイント

第3章調査手法

第4章インスリン市場- 市場情勢

第5章インスリン市場-主要な市場力学

第6章インスリン市場-世界分析

第7章インスリン市場分析-タイプ別

第8章インスリンの世界市場- 地域別分析

第10章インスリン市場-業界情勢

第11章企業プロファイル

第12章付録